| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1083783263 |
| P356 | DOI | 10.1186/S40425-017-0216-7 |
| P932 | PMC publication ID | 5319186 |
| P698 | PubMed publication ID | 28239467 |
| P50 | author | Zainul Abedin Kapacee | Q89086158 |
| Gray Kueberuwa | Q89368674 | ||
| P2093 | author name string | David Edward Gilham | |
| Robert Edward Hawkins | |||
| Hannah Gornall | |||
| Deborah Bouvier | |||
| Erik Marcelo Alcantar-Orozco | |||
| P2860 | cites work | Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen | Q24623215 |
| Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? | Q27002575 | ||
| Two subsets of memory T lymphocytes with distinct homing potentials and effector functions | Q28146072 | ||
| Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 | Q29616128 | ||
| Cytokine profiles amongst Sudanese patients with visceral leishmaniasis and malaria co-infections | Q33624814 | ||
| Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells | Q33831940 | ||
| Early events governing memory CD8+ T-cell differentiation | Q34013557 | ||
| Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype | Q34399707 | ||
| T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. | Q34621730 | ||
| SPICE: exploration and analysis of post-cytometric complex multivariate datasets | Q34769778 | ||
| Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy | Q34936175 | ||
| Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells | Q35202343 | ||
| Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice | Q35223241 | ||
| Granzyme B secretion by human memory CD4 T cells is less strictly regulated compared to memory CD8 T cells | Q35269599 | ||
| Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype | Q35849686 | ||
| Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates | Q36183567 | ||
| A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer | Q36299662 | ||
| Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression | Q36327111 | ||
| Superior T memory stem cell persistence supports long-lived T cell memory | Q36580362 | ||
| Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy | Q36908563 | ||
| Transforming growth factor-beta and the immune response: implications for anticancer therapy | Q36944384 | ||
| Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer | Q37233539 | ||
| Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. | Q37389018 | ||
| Cellular and molecular mechanisms of memory T-cell survival | Q37403487 | ||
| Biochemical signaling pathways for memory T cell recall | Q37418406 | ||
| Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. | Q37418499 | ||
| Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. | Q38094968 | ||
| Gene-engineered T cells for cancer therapy | Q38123667 | ||
| The who's who of T-cell differentiation: human memory T-cell subsets | Q38164599 | ||
| Humanized NOD-SCID IL2rg–/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. | Q38186890 | ||
| Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition | Q38199350 | ||
| CAR T-cell therapy: toxicity and the relevance of preclinical models. | Q38525018 | ||
| A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs | Q38525134 | ||
| Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy | Q38777377 | ||
| Tissue-specific attenuation of oncolytic sindbis virus without compromised genetic stability. | Q39020996 | ||
| Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial. | Q39320917 | ||
| Generation of memory T cells for adoptive transfer using clinical-grade anti-CD62L magnetic beads | Q41160104 | ||
| Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells | Q42557896 | ||
| MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation | Q42820324 | ||
| Lentiviral vector gene transfer into human T cells. | Q45882143 | ||
| Chimeric antigen receptors for T-cell based therapy | Q50058617 | ||
| Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. | Q50489657 | ||
| Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. | Q51968264 | ||
| Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses | Q70166581 | ||
| Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines | Q78952589 | ||
| The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells | Q81829557 | ||
| Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience | Q83222464 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| P304 | page(s) | 14 | |
| P577 | publication date | 2017-02-21 | |
| P1433 | published in | Journal for Immunotherapy of Cancer | Q27725163 |
| P1476 | title | CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo | |
| P478 | volume | 5 |
| Q58557193 | A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells |
| Q92700219 | Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients |
| Q52715364 | Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. |
| Q91871527 | Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies |
Search more.